Biopharmaceutical Market Size & Share 2025 - 2034

Biopharmaceutical Market Size

The global biopharmaceutical market was estimated at USD 422.5 billion in 2024. The market is expected to grow from USD 453.7 billion in 2025 to USD 921.5 billion in 2034, at a CAGR of 8.2%. The market is rapidly expanding because of the increasing demand for advanced biologics, targeted therapies, and rising prevalence of chronic and rare diseases.

According to the World Health Organization (WHO), cancer continues to be among the top causes of death globally, with almost 10 million deaths in 2023. Autoimmune disorders such as rheumatoid arthritis and multiple sclerosis affect over 20 million people globally. Additionally, the increasing burden of diabetes, with more than 537 million adults diagnosed globally, shows the need for better biopharmaceuticals.
 

Treatment results are significantly improved by the introduction of new monoclonal antibodies, recombinant proteins, and cell and gene therapies which have revolutionized the treatment of oncology, immunology and neurology. Moreover, the rise of biosimilars is making biologic treatments more accessible, adding to market expansion. The use of mRNA vaccines and therapies, mainly for the treatment of infectious diseases, is helping the biopharmaceuticals market grow.
 

Furthermore, the use of AI technologies in drug discovery, bioprocess optimization, and personalized medicine is improving research and development effectiveness while managing costs and speeding up the introduction of new therapies to the market. The growing investment in biopharmaceutical research together with improved market regulations and strong pipeline developments is expected to drive the growth of the market in the coming years.
 

The market includes the research, development, production, and marketing of biologic medicines such as monoclonal antibodies, vaccines, gene therapies, and biosimilars. These therapies, derived from living organisms, are used to combat many diseases and have remarkable efficiency and accuracy toward treatment.
 

Biopharmaceutical Market Trends

• The market is witnessing robust growth due to rising demand for biologic therapies, increasing incidence of chronic diseases, and continuous advancements in drug development and manufacturing.
   
• The increasing global burden of chronic diseases is a key driver of market expansion. The World Health Organization (WHO) estimates that cancer cases are anticipated to grow from 20 million in 2024 to 30 million by 2040 which will drastically increase the need for monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapies.
   
• Growth in the market is also being driven by the rising prevalence of diabetes. According to the International Diabetes Federation (IDF) an estimated 537 million adults live with diabetes worldwide, a figure expected to rise to 643 million by 2030. This increase in patients requires more production of biopharmaceutical insulin and GLP-1 receptor agonists.
   
• In addition, the growing incidence of obesity and lysosomal storage disorders (LSDs) is driving the demand for biologics. The WHO reports that in 2023 more than one billion people are obese and 30% of the global population suffers from non-alcoholic fatty liver disease (NAFLD).
   
• Moreover, infectious diseases continue to shape the biopharmaceutical industry, with HIV/AIDS affecting 38 million people and tuberculosis causing 1.25 million deaths in 2023 as per WHO.
   
• According to the National Institutes of Health (NIH), autoimmune diseases impact nearly 10% of the global population, with over 80 distinct conditions, including rheumatoid arthritis, lupus, and multiple sclerosis. The adoption of biologic DMARDs (disease-modifying anti-rheumatic drugs) is improving patient outcomes and expanding market size.
   
• Further, the biopharmaceutical industry is driven by neurological diseases that alone affect over a billion people worldwide according to a WHO report. Alzheimer’s disease cases are projected to rise from 55 million to 139 million by 2050, increasing demand for monoclonal antibodies and neuroprotective biologics. Similarly, biologic DMARDs are transforming multiple sclerosis and Parkinson’s disease treatment.
   
• As a result of these trends, regulatory agencies such as the U.S. FDA and European Medicines Agency (EMA) have facilitated the introduction of new biologics with fewer restrictions, thereby enabling more rapid patient access to innovative therapies.
   
• Lastly, the industry is also being transformed by improved AI powered drug discovery, automation in biomanufacturing and development of biosimilars. The global market is expected to expand steadily, driven by increasing investment in personalized medicine, immunotherapies, and next-generation biologics.
   

Biopharmaceutical Market Analysis

Based on the product type, the market is segmented into monoclonal antibody, vaccine, hormone, erythropoietin, insulin, growth and coagulation factor, interferon, and other products. The monoclonal antibody segment dominated the market with USD 196.9 billion in 2021, USD 210.3 billion in 2022 and USD 225 billion in 2023.
 

• The monoclonal antibody (mAb) segment is driving the market due to its effectiveness in treating complex diseases such as cancer, autoimmune disorders, and infectious diseases.
   
• The advancements in biotechnology, increasing incidence of chronic diseases, and growing FDA approvals are boosting this segment’s market growth. Blockbuster mAbs such as Keytruda (Merck), Humira (AbbVie), and Herceptin (Roche) have led market expansion.
   
• With the increasing popularity of biosimilars, the market is becoming more competitive and treatment costs are reducing. Emerging trends include next-generation mAbs, bispecific antibodies, and conjugated antibodies that make treatments more effective.
   
• Support from regulatory bodies and the growing need and acceptance have made mAbs an important part of modern medicine.

Learn more about the key segments shaping this market

Download Free PDF

Based on applications, the biopharmaceutical market is divided into oncology, blood disorders, infectious diseases, metabolic diseases, cardiovascular diseases, neurological diseases, immunology, and other applications. The oncology segment accounted for a significant market share of 30.9% in 2024.
 

• The global market in oncology is expanding due to rising cancer cases, increased use of biopharmaceuticals, and advances in biological therapies. According to the American Cancer Society, the U.S. recorded approximately 2 million new cancer cases and 609,820 cancer-related deaths in 2024. Breast, lung, prostate, and colorectal cancers remain among the most commonly diagnosed cancers worldwide.
   
• Cancer treatment has changed through new developments including monoclonal antibodies, CAR T-cell therapy and immune checkpoint inhibitors. Biological therapies target specific molecules or pathways that are important for cancer cell growth and spread. The use of monoclonal antibodies, including Trastuzumab (Herceptin), Bevacizumab (Avastin), and Alectinib (Alecensa), continues to grow in cancer treatment.
   
• PD-1/PD-L1 inhibitors, particularly pembrolizumab and nivolumab, have helped improve survival rates in patients with various types of cancer. Bispecific antibodies and antibody drug conjugates (ADCs) are becoming promising options in targeted therapy.
   
• The FDA has made the approval process faster for new biologics, with more than 25 cancer biologics receiving approval in 2023. The move toward personalized medicine and combination immunotherapies is creating more treatment options and helping improve patient health and quality of life.
   

Based on drug type, the biopharmaceutical market is divided into proprietary (branded) and biosimilars. The proprietary (branded) segment dominated the market in 2024 and is expected to reach USD 714.3 billion by 2034.
 

• Continuous innovation, patent protection, and significant investment in biologic drug development are key factors driving the branded drug market growth.
   
• Branded biologics are the original, first-to-market formulations of biologic medications. These drugs are created through extensive research and clinical trials, showing improved effectiveness in treating complex conditions such as autoimmune diseases, cancer, and rare genetic disorders. The increasing occurrence of these illnesses, along with the rising prescription rates of branded medications for their treatment, contributes to market expansion.
   
• As reported by the U.S. Food and Drug Administration, branded drugs make up more than 40% of total prescription drug spending in the U.S., highlighting their growing importance in modern healthcare.
   
• Patent exclusivity gives a competitive advantage by delaying the introduction of biosimilars, thus ensuring strong market dominance for manufacturers. However, despite their effectiveness, branded biologics face challenges due to their high costs.
   

Based on manufacturing type, the biopharmaceutical market is divided into outsource and in-house. The outsource segment dominated the market in 2024 with USD 233.5 billion.     
 

• The outsourced biopharmaceutical manufacturing segment is expanding rapidly due to rising demand for cost-effective production, specialized expertise, and regulatory compliance.
   
• Contract Development and Manufacturing Organizations (CDMOs) and Contract Manufacturing Organizations (CMOs) provide end-to-end solutions, including biologic drug development, production, and packaging.
• Outsourcing is especially important for monoclonal antibody and vaccine production as well as cell and gene therapies, which require specialized bioprocessing skills.
   
• By contracting out certain activities, pharmaceutical firms can dedicate more resources to research and development and use specialized bioprocessing services offered by other companies.
   
• The increasing complexity of regulations, the need for compliance with Good Manufacturing Practices (GMPs), and expensive capital investments are the main contributors to this development.
   

Based on route of administration, the biopharmaceutical market is divided into injectables, oral, and other routes of administration. The injectables segment dominated the market in 2024 with USD 364.9 billion.    
 

• The injectables segment dominates the market, driven by its high bioavailability, rapid drug action, and effectiveness in delivering biologics such as monoclonal antibodies, vaccines, and insulin.
   
• Injectable formulations are essential for treating cancer, autoimmune diseases, diabetes, and infectious diseases, where oral alternatives are less effective. With advancements in prefilled syringes, autoinjectors,and intravenous infusions, patient compliance and convenience have improved significantly.
   
• The growing prevalence of chronic diseases and the demand for self-administered biologics further support market expansion. Regulatory approvals for novel injectable biologics, including mRNA vaccine and gene therapy, continue to drive growth in this segment.
   

Based on prescription type, the biopharmaceutical market is divided into prescription medicines and over the counter (OTC) medicines. The prescription medicines segment dominated the market in 2024 with USD 385.6 billion.    
 

• The prescription medicines segment plays a dominant role in the market, as most biologics need medical supervision due to their complexity and possible side effects.
   
• These drugs, including monoclonal antibodies, gene therapies, and recombinant proteins, are important for treating cancer, autoimmune disorders, diabetes, and rare genetic disorders.
   
• Strict regulatory approvals ensure safety and effectiveness, with agencies like the FDA and EMA overseeing drug authorization. Advances in personalized medicine and targeted therapies are increasing treatment options.
   
• Despite high costs, insurance coverage and reimbursement policies help patients access these medicines, driving the continued growth of prescription biopharmaceuticals.
   

Based on distribution channel, the biopharmaceutical market is divided into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2024 and is expected to reach USD 605.6 billion by 2034.
 

• The hospital pharmacies segment is important for distributing biopharmaceuticals because it provides specialized and expensive biologics to inpatient and outpatient care.
   
• These pharmacies manage the storage and administration of temperature-sensitive biologics, including vaccines, monoclonal antibodies, and gene therapies.
   
• Hospital pharmacies play an important role in medication management, dose optimization, and patient safety, especially for critical treatments such as chemotherapy, immunotherapy, and rare disease biologics.
   
• With the increasing use of biosimilars and personalized medicine, hospital pharmacies are expanding their capabilities to support advanced therapies and specialized care models for complex diseases.

The North America biopharmaceutical market held the largest market share of 43% in 2024 in the global market, and it is anticipated to expand at 8.1% CAGR over the forecast period. The U.S. market was valued at USD 135.2 billion in 2021. The market size was valued at USD 144.7 billion in 2022 and reached USD 155.2 billion in 2023.
 

• The biopharmaceutical sector in the U.S. is crucial to the advancement of drug development, supported by research initiatives, technological innovations, and regulatory systems.
   
• This sector operates through a collaborative network of pharmaceutical corporations, biotechnology enterprises, and academic organizations. It is influenced by new trends in biologics, gene therapy, and precision medicine, which are creating approaches for new treatment methods.
   
• However, the industry faces challenges, including pricing pressures, patent expirations, and complex regulatory requirements. As there is a growing focus on personalized healthcare and the use of digital technologies, the market continues to evolve, impacting medical advancements and patient care on a global scale.
•  

Europe biopharmaceutical market accounted for USD 118.4 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The European biopharmaceutical sector benefits from government investments, research organizations, and regulatory authorities like the European Medicines Agency (EMA).
   
• It includes a diverse network of pharmaceutical and biotechnology firms that work on developing biologics, biosimilars, and advanced therapeutic solutions. The market operates under strict regulations, intellectual property frameworks, and healthcare policies that vary across countries.
   
• The industry faces challenges like pricing regulations, barriers to market entry, and competition from generic products. However, with ongoing investments in personalized medicine and innovations in biotechnology, the sector continues to grow to meet changing healthcare needs and technological advancements in the region.
   

The Germany biopharmaceutical market is experiencing robust growth in Europe market.
 

• Germany has one of Europe's largest markets, supported by established research institutions, government initiatives, and a robust pharmaceutical industry.
   
• Lung and bronchial cancers accounted for approximately 30% of cancer-related deaths in Germany in 2023, driving demand for biopharmaceutical treatments, particularly targeted therapies, immunotherapies, and oncology biologics.
   
• The country maintains a significant position in biologics, biosimilars, and advanced therapy development, with multiple biotech and pharmaceutical companies conducting drug research.
   

The Asia Pacific biopharmaceutical market witnessed substantial growth of 8.5% during the analysis period.
 

• The Asia-Pacific market is experiencing significant growth due to increasing healthcare demand, government investments, and an expanding biotechnology sector.
   
• China, Japan, and India are emerging as primary markets, with significant developments in biologics, biosimilars, and cell and gene therapies. The diverse regulatory frameworks across countries affect market access and drug approval processes. The market faces challenges including intellectual property protection, pricing pressures, and competition from domestic manufacturers.
   
• The region's biopharmaceutical sector continues to strengthen through increased research and development investments, collaborations with international companies, and emphasis on personalized medicine and digital health technologies. These factors establish Asia-Pacific as a significant contributor to global biopharmaceutical development and manufacturing.
   

The Brazil biopharmaceutical market is experiencing robust growth in Latin America market.
 

• Brazil has the largest market in Latin America, driven by government healthcare programs, biotechnology industry growth, and increasing demand for advanced therapies.
   
• The National Health Surveillance Agency (ANVISA) provides the regulatory framework for drug approvals and market entry.
   
• The market shows substantial growth in biologics, biosimilars, and vaccine manufacturing, supported by domestic and international companies.
   

The Saudi Arabia biopharmaceutical market is witnessing substantial growth in Middle East and Africa.
 

• The Saudi Arabian market is expanding due to government initiatives, healthcare investments, and efforts to develop local drug production.
   
• The Saudi Food and Drug Authority (SFDA) regulates the industry to maintain international standards. The market focuses on biologics, biosimilars, and vaccine development through research investments and local manufacturing facilities.
   
• The government's Vision 2030 strategy promotes pharmaceutical innovation, international partnerships, and domestic manufacturing to reduce import dependence and improve healthcare delivery.
   

Biopharmaceutical Market Share

The top 5 companies in the market, such as AbbVie, F. Hoffmann-La Roche, AstraZeneca, Bayer, and Novartis account for ~60% of the market share. These companies maintain their dominance through advancements in immuno-oncology, biologics, and personalized medicine, catering to the growing demand for specialized treatments in oncology, neurology, and autoimmune diseases.
 

Firms are expanding their portfolios with gene therapies, monoclonal antibodies, and cell-based treatments to enhance precision medicine. For example, Eli Lilly and Company and Merck focus on oncology therapies, while Pfizer and Johnson & Johnson develop vaccines and immunotherapies. Companies are investing heavily in AI-driven drug discovery, digital health solutions, and advanced biologics, driving innovation and competition in the biopharmaceutical sector.
 

Biopharmaceutical Market Companies

Major players operating in the biopharmaceutical industry are:

• AbbVie
• Amgen
• AstraZeneca  
• Bayer 
• Biogen
• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffmann-La Roche        
• GlaxoSmithKline       
• Johnson & Johnson  
• Merck
• Novartis       
• Novo Nordisk
• Pfizer
• Sanofi
• Sandoz        
• Takeda Pharmaceutical
   
• AbbVie specializes in immunology and oncology therapies, with its bestseller drug Humira (adalimumab) leading the market in treating autoimmune diseases. The company is also advancing gene therapies for hematologic cancers, focusing on precision medicine to improve treatment outcomes.
   
• Amgen is a leader in biologics, with key therapies such as Enbrel (etanercept) for rheumatoid arthritis and Prolia (denosumab) for osteoporosis. Amgen is also expanding its oncology pipeline with innovative treatments, including bispecific T-cell engagers and CAR T-cell therapies, to enhance cancer care.
   
• AstraZeneca focuses on oncology, cardiovascular, and respiratory treatments, with key drugs such as Tagrisso (osimertinib) for lung cancer and Farxiga (dapagliflozin) for diabetes and heart failure. The company is investing in AI-driven drug discovery and next-generation biologics to address unmet medical needs in oncology and metabolic diseases.
   

Biopharmaceutical Industry News

• In February 2025, Biogen Inc. and Stoke Therapeutics Inc. formed a collaboration to develop and commercialize zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome, a severe form of epilepsy. This strategy will add value to the company's business portfolio.
   
• In October 2024, AbbVie and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop next-generation cancer biotherapeutics. The partnership will use EvolveImmune's EVOLVE T-cell engager platform to create multispecific antibody-based therapies targeting solid and hematologic malignancies.
   
• In December 2023, Bristol Myers Squibb and SystImmune entered a global strategic collaboration to develop and commercialize BL-B01D1, a bispecific antibody-drug conjugate for solid tumors. The partnership aims to advance innovative oncology treatments by using both companies' expertise in biopharmaceutical development.
   

The biopharmaceutical market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Monoclonal antibody
• Vaccine
• Hormone
• Erythropoietin
• Insulin
• Growth and coagulation factor
• Interferon
• Other product types

Market, By Application

• Oncology
• Blood disorders
• Infectious diseases
• Metabolic diseases
• Cardiovascular diseases
• Neurological diseases
• Immunology
• Other applications

Market, By Drug Type

• Proprietary (Branded)
• Biosimilars

Market, By Manufacturing Type

• Outsource
• In-house

Market, By Route of Administration

• Injectables
• Oral
• Other routes of administration

Market, By Prescription Type

• Prescription medicines
• Over the counter (OTC) medicines

Market, By Distribution Channel

• Hospital pharmacies
• Drug stores and retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE